MX366234B - Purificacion de particulas tipo virus. - Google Patents

Purificacion de particulas tipo virus.

Info

Publication number
MX366234B
MX366234B MX2014015842A MX2014015842A MX366234B MX 366234 B MX366234 B MX 366234B MX 2014015842 A MX2014015842 A MX 2014015842A MX 2014015842 A MX2014015842 A MX 2014015842A MX 366234 B MX366234 B MX 366234B
Authority
MX
Mexico
Prior art keywords
particles
virus
purification
methods
vlps
Prior art date
Application number
MX2014015842A
Other languages
English (en)
Other versions
MX2014015842A (es
Inventor
Taylor Ross
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2014015842A publication Critical patent/MX2014015842A/es
Publication of MX366234B publication Critical patent/MX366234B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos de purificación de partículas tipo virus (VLP), sustancialmente libres de contaminantes de proceso y agentes infecciosos. Los métodos incorporan, por ejemplo, un tratamiento a pH bajo durante la cosecha y/o inactivación con solvente y/o detergente durante la captura de las VLP.
MX2014015842A 2012-06-22 2013-06-24 Purificacion de particulas tipo virus. MX366234B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663218P 2012-06-22 2012-06-22
US201361794086P 2013-03-15 2013-03-15
PCT/US2013/047249 WO2013192604A1 (en) 2012-06-22 2013-06-24 Purification of virus like particles

Publications (2)

Publication Number Publication Date
MX2014015842A MX2014015842A (es) 2015-09-07
MX366234B true MX366234B (es) 2019-07-03

Family

ID=49769461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015842A MX366234B (es) 2012-06-22 2013-06-24 Purificacion de particulas tipo virus.

Country Status (15)

Country Link
US (3) US10167320B2 (es)
EP (1) EP2864478B1 (es)
JP (1) JP6553509B2 (es)
KR (1) KR102110876B1 (es)
CN (2) CN104583393A (es)
AR (1) AR091538A1 (es)
AU (1) AU2013277959B2 (es)
CA (1) CA2879815A1 (es)
IN (1) IN2015DN00089A (es)
JO (1) JOP20130186B1 (es)
MX (1) MX366234B (es)
SG (2) SG11201408459VA (es)
TW (1) TWI647310B (es)
UY (1) UY34875A (es)
WO (1) WO2013192604A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
KR102069561B1 (ko) * 2013-07-11 2020-01-23 다카라 바이오 가부시키가이샤 외피 비보유 바이러스의 제조 방법
JP2016533172A (ja) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド 細胞株からラブドウイルスを検出および除去する方法
CN103981084B (zh) * 2014-05-29 2015-11-18 黑龙江省科学院微生物研究所 水中病毒分离提取装置及水中札幌病毒的提取方法
CN107109374B (zh) 2015-01-09 2021-04-06 宝生物工程株式会社 用于生产无包膜病毒颗粒的方法
JP6893174B2 (ja) * 2015-01-16 2021-06-23 タケダ ワクチン，インコーポレイテッド 粒子に含まれる逆転写酵素活性の検出
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN107034198B (zh) * 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
AU2016317661B2 (en) 2015-08-28 2023-05-18 Ology Bioservices, Inc. Norovirus vaccine
CN105779399A (zh) * 2016-03-28 2016-07-20 广西壮族自治区林业科学研究院 一种昆虫杆状病毒纯化方法
GB201614050D0 (en) 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
US20190194628A1 (en) * 2016-09-01 2019-06-27 Takeda Vaccines, Inc. Methods for producing virus for vaccine production
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
ES2975182T3 (es) 2017-03-06 2024-07-03 Guangzhou Realbenefitspot Pharmaceutical Co Ltd Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica
JP2021514391A (ja) 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
CN108676781A (zh) * 2018-05-18 2018-10-19 山东信得动物疫苗有限公司 一种重组禽流感病毒的工业化纯化方法
CN108776225A (zh) * 2018-05-23 2018-11-09 中国农业科学院兰州兽医研究所 猪细小病毒VLPs抗体检测试剂盒及其制备方法、应用
US20220152186A1 (en) 2019-03-12 2022-05-19 Icon Genetics Gmbh Norovirus-like particles with improved stability
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CA3224156A1 (en) * 2021-06-28 2023-01-05 VST LLC dba Medgene Labs Sapovirus vaccines
CN116789773B (zh) * 2022-11-30 2024-02-20 华北制药金坦生物技术股份有限公司 一种胞内表达病毒样颗粒的粗纯方法
WO2025077800A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Purification of norovirus virus-like particles (vlps)
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
ES2264126T3 (es) 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3316325B2 (ja) * 1994-12-20 2002-08-19 富士シリシア化学株式会社 ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP4021493B2 (ja) 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
AU742409B2 (en) 1997-09-05 2002-01-03 Medimmune, Llc In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
DE19823814A1 (de) 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
EP1105466B1 (en) 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US6349843B1 (en) 1999-04-01 2002-02-26 The Vollrath Company Llc Pan removal ramp
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2003066021A (ja) 2001-08-28 2003-03-05 Hiroshi Shionoya 連続分取液体クロマトグラフィー装置とそれを用いる方法
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US8277819B2 (en) 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
DK2275132T3 (da) 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
EP2235165A1 (en) 2007-12-21 2010-10-06 Cytos Biotechnology AG Process for clarifying cell homogenates
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
WO2010062757A1 (en) 2008-11-03 2010-06-03 Ligocyte Pharmaceuticals, Inc. Improved methods for isolating enveloped virus-based vlps free of infectious agents
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP2013517773A (ja) 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
EP2619217B1 (en) 2010-09-20 2016-11-09 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
FI122520B (fi) 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CN102260651A (zh) 2011-06-24 2011-11-30 华中科技大学同济医学院附属协和医院 一种纯化病毒样颗粒蛋白的方法及其应用
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法

Also Published As

Publication number Publication date
CN114085273B (zh) 2024-07-12
KR102110876B1 (ko) 2020-05-14
SG10201610753YA (en) 2017-02-27
AU2013277959B2 (en) 2019-05-16
JP6553509B2 (ja) 2019-07-31
JP2015521628A (ja) 2015-07-30
US20220213147A1 (en) 2022-07-07
WO2013192604A1 (en) 2013-12-27
IN2015DN00089A (es) 2015-05-29
EP2864478B1 (en) 2020-12-09
TWI647310B (zh) 2019-01-11
EP2864478A4 (en) 2015-12-02
US20140004145A1 (en) 2014-01-02
HK1210210A1 (en) 2016-04-15
KR20150051988A (ko) 2015-05-13
US12286456B2 (en) 2025-04-29
AR091538A1 (es) 2015-02-11
US10167320B2 (en) 2019-01-01
US11091519B2 (en) 2021-08-17
JOP20130186B1 (ar) 2021-08-17
US20190169236A1 (en) 2019-06-06
AU2013277959A1 (en) 2015-01-22
CA2879815A1 (en) 2013-12-27
CN114085273A (zh) 2022-02-25
CN104583393A (zh) 2015-04-29
TW201406956A (zh) 2014-02-16
EP2864478A1 (en) 2015-04-29
MX2014015842A (es) 2015-09-07
UY34875A (es) 2013-12-31
SG11201408459VA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX2014015842A (es) Purificacion de particulas tipo virus.
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
EA201790630A1 (ru) Способы получения рибозидов
PH12017501258A1 (en) Pyrazine compounds for the treatment of infectious diseases
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201391152A1 (ru) Ингибиторы вируса гепатита с
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
SG11201406407TA (en) Methods for inactivating viruses during a protein purification process
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
WO2016099982A3 (en) Phosphoramidates for the treatment of hepatitis b virus
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
CL2014000469A1 (es) Compuestos derivados del acido 2-oxo-6-(aril/heteroaril)-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; tratamiento combinado; y un metodo de tratamiento de una infeccion bacteriana.
MY161252A (en) Viral inactivation using improved solvent-detergent method
EA201370017A1 (ru) Ингибиторы вируса гепатита с
PH12013502442A1 (en) Inactivated dengue virus vaccine
PH12013502177A1 (en) Hepatitis c virus inhibitors
EA201692034A1 (ru) Новые макроциклические соединения
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112017006589A2 (pt) um método de purificação de lignina por sujeição de uma pasta fluida compreendendo lignina para um campo elétrico
WO2012006149A3 (en) Analogs of c5a and methods of using same
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
EP2731507A4 (en) IMPLANTS, TOOLS, AND METHODS FOR TREATING PELVIC DISEASES
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
WO2013005042A3 (en) Anti-viral therapy

Legal Events

Date Code Title Description
FG Grant or registration